Royalty Pharma plc (RPRX) ownership: RPI US Partners 2019, LP 19% · institutions 54% · index and ETF funds 12% (13F 2026-03-31). Insider activity, 90 days: Routine (11 sales, 0 open-market buys). SEC EDGAR first-party data.
| Holder | Shares | Market Value | % Outstanding | Reported |
|---|---|---|---|---|
| Capital Group | 45809133.00 | $2.20B | 8.2% | 2026-03-31 |
| Morgan Stanley | 43571633.00 | $2.09B | 7.8% | 2026-03-31 |
| BlackRock | 25907745.00 | $1.24B | 4.7% | 2026-03-31 |
| FMR (Fidelity) | 25152242.00 | $1.21B | 4.5% | 2026-03-31 |
| Baillie Gifford | 16155677.00 | $774.99M | 2.9% | 2026-03-31 |
| Swedbank | 11586693.00 | $555.81M | 2.1% | 2026-03-31 |
| State Street | 10989851.00 | $527.18M | 2.0% | 2026-03-31 |
| Vanguard | 10096618.00 | $484.33M | 1.8% | 2026-03-31 |
| Insider | Transaction | Value | Date |
|---|---|---|---|
| Sell | null | 2026-08-18 | |
| Sell | null | 2026-08-18 | |
| Sell | null | 2026-08-13 | |
| Sell | null | 2026-08-13 | |
| Sell | null | 2026-08-05 | |
| Sell | null | 2026-08-05 | |
| Sell | null | 2026-08-05 | |
| Sell | null | 2026-08-05 |
Back to RPRX overview · RPRX earnings · All congressional trades
Institutional data from SEC Form 13F. Insider data from SEC Form 4. Congressional data from STOCK Act disclosures. Not personalized investment advice.